alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

28,180 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 526–550 of 777 studies with an author at University of California, San Francisco (US) (page 22 of 32) · 28,180 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 13,658 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Heightened emotional contagion in mild cognitive impairment and Alzheimer's disease is associated with temporal lobe degeneration

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Proceedings of the National Academy of Sciences of the United States of America 2013-05-28

Emotional changes are common in mild cognitive impairment (MCI) and Alzheimer's disease (AD). 5 key findings →

Participants: 237 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Characterizing Alzheimer's disease using a hypometabolic convergence index

✓ Peer-reviewed alzhub usefulness score 51 out of 100. NeuroImage 2011-01-27

This article introduces a hypometabolic convergence index (HCI) for the assessment of Alzheimer's disease (AD); compares it to other biological, cognitive and clinical measures; and demonstrates its promise to predict clinical decline in mild cognitive impairment (MCI) patients using data from the AD Neuroimaging Initiative (ADNI). 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Upregulation of TREM2 ameliorates neuropathology and rescues spatial cognitive impairment in a transgenic mouse model of Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2014-07-22

Triggering receptor expressed on myeloid cells 2 (TREM2) gene is a recently identified susceptibility gene for Alzheimer's disease (AD), as its low-frequency variants increase the risk of this disease with an odds ratio similar to that of an APOE ɛ4 allele. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Neurology(R) neuroimmunology & neuroinflammation 2018-11-07

CSF sTREM2 increased with systemic and CNS HIV-1 disease severity, with the highest levels found in patients with HIV-associated dementia (HAD). 4 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Diffusion MRI Indices and Their Relation to Cognitive Impairment in Brain Aging: The Updated Multi-protocol Approach in ADNI3

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Frontiers in neuroinformatics 2019-02-19

Brain imaging with diffusion-weighted MRI (dMRI) is sensitive to microstructural white matter (WM) changes associated with brain aging and neurodegeneration. 4 key findings →

Participants: 317 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Confirmatory factor analysis of the ADNI Neuropsychological Battery

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Brain imaging and behavior 2012-12-01

The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a large multi-center study designed to develop optimized methods for acquiring longitudinal neuroimaging, cognitive, and biomarker measures of AD progression in a large cohort of patients with Alzheimer's disease (AD), patients with Mild Cognitive Impairment, and healthy controls. 4 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Heritability for Alzheimer's disease: the study of dementia in Swedish twins

✓ Peer-reviewed alzhub usefulness score 51 out of 100. The journals of gerontology. Series A, Biological sciences and medical sciences 1997-03-01

Alzheimer's disease has been thought to have familial and sporadic forms, and several genetic defects have been identified that chiefly explain early-onset familial cases. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Association of neighborhood disadvantage with Alzheimer's disease pathology and the stability of blood-based biomarker performance

✓ Peer-reviewed alzhub usefulness score 51 out of 100. The Journal of Prevention of Alzheimer s Disease 2025-11-23

ADI groups differed by sex, ethnoracial background, and MMSE scores. 5 key findings →

Design: cohort study Participants: 755 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Alzheimer's Disease Neuroimaging Initiative: Two decades of pioneering Alzheimer's disease research and future directions

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Alzheimer s & Dementia 2025-01-01

This special issue of Alzheimer's & Dementia celebrates the accomplishments of the Alzheimer's Disease Neuroimaging Initiative (ADNI) project as it approaches its 20th anniversary in 2024, supported by funding from the National Institute on Aging. 1 key finding →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Cardiovascular risk factors and the allostatic interoceptive network in dementia

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Cardiovascular Research 2025-10-01

We recruited 1501 participants (304 with FTLD, 512 with AD, and 685 healthy controls) from the Multi-Partner Consortium to Expand Dementia Research in Latin America (ReDLat). 5 key findings →

Participants: 1,501 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Cryptic splicing in synaptic and membrane excitability genes links TDP-43 loss to neuronal dysfunction

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Science Translational Medicine 2026-06-03

Using human stem cell-derived neurons, we show that TDP-43 reduction induces cryptic splicing and downregulation of these genes, resulting in impaired excitability and synaptic transmission. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Continued Use of Cholinesterase Inhibitors and Memantine in Hospice

✓ Peer-reviewed alzhub usefulness score 51 out of 100. JAMA Internal Medicine 2025-03-24

This cohort study examines the use of cholinesterase inhibitors and memantine among older adults with dementia after admission into hospice care despite the medications’ limited clinical benefit following enrollment into hospice. 1 key finding →

Design: cohort study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

Caregiving and the Stress Process: An Overview of Concepts and Their Measures

✓ Peer-reviewed alzhub usefulness score 51 out of 100. The Gerontologist 1990-10-01

This paper views caregiver stress as a consequence of a process comprising a number of interrelated conditions, including the socioeconomic characteristics and resources of caregivers and the primary and secondary stressors to which they are exposed.

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Central Nervous System Lipoproteins: ApoE and Regulation of Cholesterol Metabolism

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Arteriosclerosis, thrombosis, and vascular biology 2016-05-12

ApoE on high-density lipoproteins is primarily responsible for lipid transport and cholesterol homeostasis in the central nervous system (CNS). 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

"Thinking about it for somebody else": Alzheimer's disease research and proxy decision makers' translation of ethical principles into practice

✓ Peer-reviewed alzhub usefulness score 50 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2013-02-06

Tensions exist between abstract ethical principles regarding decision-making "standards" and their translation into research decisions. 3 key findings →

Participants: 40 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases 2009-06-01

Amyotrophic lateral sclerosis (ALS) is increasingly recognized to be a multisystem disorder which includes both clinical and neuropathological features of a frontotemporal lobar degeneration (FTLD). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

A clinicopathological approach to the diagnosis of dementia

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Nature reviews. Neurology 2017-07-14

The most definitive classification systems for dementia are based on the underlying pathology which, in turn, is categorized largely according to the observed accumulation of abnormal protein aggregates in neurons and glia. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 28,180 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 28,180 records, built mostly from automated pulls of Europe PMC (61.7% of the library) and OpenAlex (18.1%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,034 records (3.7% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed